Adam D. Cohen, MD

Articles

Dr Cohen on Efforts Needed to Unmet Needs in R/R Multiple Myeloma

June 2nd 2023

Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.

Dr. Cohen on the Use of CAR T-cell Therapy in Earlier Lines of Multiple Myeloma Treatment

March 15th 2023

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Dr. Cohen on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

August 28th 2022

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Dr. Cohen on the Safety Profile of Cilta-Cel in Multiple Myeloma

October 28th 2021

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Dr. Cohen on CARTITUDE-2 Data With Cilta-Cel in Multiple Myeloma

September 27th 2021

Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.

Dr. Cohen on Mitigation Strategies for CAR T-Cell Therapy in Multiple Myeloma

September 21st 2021

Adam D. Cohen, MD, discusses mitigation strategies that can be used for patients with relapsed/refractory multiple myeloma who are receiving the CAR T-cell therapy ciltacabtagene autoleucel.

Dr. Cohen on the DREAMM-2 Trial in Multiple Myeloma

October 31st 2019

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.